CDDF Annual Conference 2022

Towards a Collaborative Future in Patient Access

7-9 February 2022
Noordwijk aan Zee, NL

Meeting Secretariat
Cancer Drug Development Forum (CDDF) – info@cddf.org

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Close Chapelle-aux-Champs 30, 1200 Brussels, Belgium
Register of legal entities: The French Speaking Enterprise Court in Brussels|Enterprise number: 738.523.752
Email: info@cddf.org|Website: www.cddf.org

EVENT OUTLINE

The Cancer Drug Development Forum (CDDF) Annual conference is a unique meeting that gathers the leaders in the world of innovative cancer therapy development, including medical researchers, pharmaceutical industry representatives, regulatory authority representatives and patient advocacy groups. In 2022, the annual conference will be organised in a hybrid format from 7 to 9 February 2022 in Noordwijk aan Zee (NL).

This multi-stakeholder, interactive meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities. The programme will focus on the way towards a collaborative future in patient access with a special emphasis on the following topics:

- Integration of Regulatory Assessment and the Assessment of Reimbursement
- Enhancing the Future of Clinical Trials
- Acceleration in the Pediatric Programs
- Collaboration in the Post-Covid Regulatory Environment.

PROGRAMME COMMITTEE

- Jaap Verweij (CDDF Board)
- Claudia Hey (Merck Healthcare KGaA)
- Michael Zaiac (Novartis)
- Roger Wilson (WECAN / SPAEN)
- Kim H. Lyerly (AAADV, US)

COMMITTEE ADVISOR

- Ralf Herold (EMA)

TARGET AUDIENCE

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocates.

EXPECTED NUMBER OF PARTICIPANTS:

Onsite: +/- 80 participants
Online: +/- 80 participants

MEETING DATE:

Monday 7 – Wednesday 9 February 2022

MEETING VENUE:

TBC

DRAFT PROGRAMME

(last updated on 8 July 2021)

DAY 1 – Monday 7 February 2022

Session 1: Integration of Regulatory Assessment and the Assessment of Reimbursement

13:00-13:25 **Adaptive Pathway Development: a Clinical Approach in Fabry Disease**

13:25-13:50 **ILAP - Co-Operation and Accelerated Approval**

13:50-14:15 **Industry perspective**

14:15-14:35 **De-Risking / Different Endpoints with Different Purposes.**

14:35-15:15 **Panel discussion (40')**

15:15-15:45 **Coffee break (30')**

Session 2: Reflection on CDDF Workshops 2021

15:45-16:00 **Endpoints in Cancer Drug Development**
16:00-16:15 Discussion (15')

16:15-16:30 **Digital Tools and AI**
16:30-16:45 Discussion (15')

16:45-17:00 **Gene and Cell Therapies**
17:00-17:15 Discussion (15')

19:00-22:00 Networking dinner (off-site)

DAY 2 – Tuesday 8 February 2022

Session 3: Enhancing the Future of Clinical Trials

09:00-09:20 TBC
09:20-09:40 TBC
09.40-10:00 TBC
10.00-10.20 TBC

10.20-10:45 **Coffee break (25')**

10:45-11:45 Q&A and panel discussion

Session 4: Lessons learned from Acceleration in Pediatric Oncology Programs

14.00-14.30 TBC
14.30-15.00 TBC
15.00-15.30 TBC

15:30-16:00 **Coffee break (30')**

16:15-17.00 Q&A and panel discussion

17.00-19.00 Free for individual interactions

19:00-22:00 Networking dinner (hotel)

DAY 3 – Wednesday 9 February 2022

Session 5 - Collaboration in the Post-Covid Regulatory Environment

09:00-10:15	TBC
10:15-10:45	**Coffee Break**
10:45-12:00	TBC
12:00-13:00	take away lunch & departure of participants